These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 11147584

  • 21. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
    Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS.
    Cancer; 1995 Apr 15; 75(8):2123-31. PubMed ID: 7697603
    [Abstract] [Full Text] [Related]

  • 22. p53 mutations in benign breast tissue.
    Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold L, Melton LJ.
    J Clin Oncol; 1995 Sep 15; 13(9):2293-300. PubMed ID: 7666086
    [Abstract] [Full Text] [Related]

  • 23. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
    Chitemerere M, Andersen TI, Holm R, Karlsen F, Børresen AL, Nesland JM.
    Breast Cancer Res Treat; 1996 Sep 15; 41(2):103-9. PubMed ID: 8944328
    [Abstract] [Full Text] [Related]

  • 24. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.
    Rosenthal SI, Depowski PL, Sheehan CE, Ross JS.
    Appl Immunohistochem Mol Morphol; 2002 Mar 15; 10(1):40-6. PubMed ID: 11893034
    [Abstract] [Full Text] [Related]

  • 25. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis.
    Murphy DS, Hoare SF, Going JJ, Mallon EE, George WD, Kaye SB, Brown R, Black DM, Keith WN.
    J Natl Cancer Inst; 1995 Nov 15; 87(22):1694-704. PubMed ID: 7473818
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL.
    Hum Pathol; 1992 Sep 15; 23(9):974-9. PubMed ID: 1355464
    [Abstract] [Full Text] [Related]

  • 29. The evaluation of the immunoexpression of Her2÷neu oncoprotein in ductal carcinoma in situ in association with invasive ductal carcinoma of the breast.
    Fota GL, Stepan A, Ciurea RN.
    Rom J Morphol Embryol; 2012 Sep 15; 53(3 Suppl):805-10. PubMed ID: 23188444
    [Abstract] [Full Text] [Related]

  • 30. Genetic analysis of HER-2/neu gene amplification in paraffin embedded tumour tissue in women with breast cancer.
    Zadrozny M, Smolarz B, Romanowicz-Makowska H, Kozłowska E, Kulig A.
    Pol J Pathol; 2002 Sep 15; 53(4):189-93. PubMed ID: 12597335
    [Abstract] [Full Text] [Related]

  • 31. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast.
    Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E.
    Cancer Res; 1996 Nov 15; 56(22):5260-5. PubMed ID: 8912866
    [Abstract] [Full Text] [Related]

  • 32. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q, Li Y, Mu K, Li Z, Meng Q, Wu X, Wang Y, Li L.
    Diagn Pathol; 2014 Mar 25; 9():71. PubMed ID: 24667108
    [Abstract] [Full Text] [Related]

  • 33. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer.
    Iacopetta B, Grieu F, Powell B, Soong R, McCaul K, Seshadri R.
    Clin Cancer Res; 1998 Jul 25; 4(7):1597-602. PubMed ID: 9676832
    [Abstract] [Full Text] [Related]

  • 34. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R, Apple SK, He J, Gornbein JA, Chang HR.
    Breast J; 2005 Jul 25; 11(6):433-9. PubMed ID: 16297088
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Extensive apoptosis in ductal carcinoma in situ of the breast.
    Bodis S, Siziopikou KP, Schnitt SJ, Harris JR, Fisher DE.
    Cancer; 1996 May 01; 77(9):1831-5. PubMed ID: 8646681
    [Abstract] [Full Text] [Related]

  • 39. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections.
    Moore JG, To V, Patel SJ, Sneige N.
    Diagn Cytopathol; 2000 Nov 01; 23(5):299-302. PubMed ID: 11074621
    [Abstract] [Full Text] [Related]

  • 40. HER-2/neu (c-erb-B2) gene and protein in breast cancer.
    Ross JS, Fletcher JA.
    Am J Clin Pathol; 1999 Jul 01; 112(1 Suppl 1):S53-67. PubMed ID: 10396301
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.